ASXL3 and small cell lung carcinoma: Furthermore, ASXL3 was found to serve as an effective biomarker for predicting the sensitivity towards BET protein inhibitors in small cell lung cancer (SCLC), highlighting its potential as an actionable biomarker [38, 39].